相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Levels of miR-29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA
Hui Yang et al.
AMERICAN JOURNAL OF HEMATOLOGY (2011)
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine
Raphael Itzykson et al.
BLOOD (2011)
Targeting Immune Dysregulation in Myelodysplastic Syndromes
Matthew J. Olnes et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Immunosuppressive Therapy for Patients With Myelodysplastic Syndrome: A Prospective Randomized Multicenter Phase III Trial Comparing Antithymocyte Globulin Plus Cyclosporine With Best Supportive Care-SAKK 33/99
Jakob R. Passweg et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Hypomethylating Agents and Other Novel Strategies in Myelodysplastic Syndromes
Guillermo Garcia-Manero et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Outcome of Patients With Myelodysplastic Syndrome After Failure of Decitabine Therapy
Elias Jabbour et al.
CANCER (2010)
Oral Clofarabine in the Treatment of Patients With Higher-Risk Myelodysplastic Syndrome
Stefan Faderl et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase I Clinical and Pharmacokinetic Study of Oral Sapacitabine in Patients With Acute Leukemia and Myelodysplastic Syndrome
Hagop Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Alemtuzumab Treatment of Intermediate-1 Myelodysplasia Patients Is Associated With Sustained Improvement in Blood Counts and Cytogenetic Remissions
Elaine M. Sloand et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Incidence and Clinical Complications of Myelodysplastic Syndromes Among United States Medicare Beneficiaries
Stuart L. Goldberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2
Myunggon Ko et al.
NATURE (2010)
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
William Blum et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
James W. Vardiman et al.
BLOOD (2009)
Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With Myelodysplastic Syndromes
Roger M. Lyons et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial
David P. Steensma et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome
R. Garg et al.
LEUKEMIA (2009)
Altered naive and memory CD4+T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome
J. X. Zou et al.
LEUKEMIA (2009)
Mechanisms of Disease: Myelodysplastic Syndromes.
Ayalew Tefferi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis
Victor Moyo et al.
ANNALS OF HEMATOLOGY (2008)
Cytogenetic features in myelodysplastic syndromes
Detlef Haase
ANNALS OF HEMATOLOGY (2008)
Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF:: the GFM experience
Sophie Park et al.
BLOOD (2008)
Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs
Dana E. Rollison et al.
BLOOD (2008)
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System
Hagop Kantarjian et al.
CANCER (2008)
Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome
Martin Jadersten et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Characteristics of US Patients with Myelodysplastic Syndromes: Results of Six Cross-sectional Physician Surveys
Mikkael A. Sekeres et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
A pilot pharmacokinetic study of oral azacitidine
G. Garcia-Manero et al.
LEUKEMIA (2008)
A prognostic score for patients with lower risk myelodysplastic syndrome
G. Garcia-Manero et al.
LEUKEMIA (2008)
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q
Azra Raza et al.
BLOOD (2008)
New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes:: evidence from a core dataset of 2124 patients
Detlef Haase et al.
BLOOD (2007)
Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders
ChunKang Chang et al.
BLOOD (2007)
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes
Luca Malcovati et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin
Z. Y. Lim et al.
LEUKEMIA (2007)
Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality
Masaaki Takatoku et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2007)
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
Hagop Kantarjian et al.
BLOOD (2007)
Current concepts in the pathophysiology and treatment of aplastic anemia
Neal S. Young et al.
BLOOD (2006)
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion
Alan List et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Decitabine improves patient outcomes in myelodysplastic syndromes - Resuits of a Phase III randomized study
H Kantarjian et al.
CANCER (2006)
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: A basis for clinical decision making
L Malcovati et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF
M Jädersten et al.
BLOOD (2005)
Efficacy of lenalidomide in myelodysplastic syndromes
A List et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes:: delayed transplantation for low-risk myelodysplasia is associated with improved outcome
CS Cutler et al.
BLOOD (2004)
A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome
Y Saunthararajah et al.
BLOOD (2003)
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B
LR Silverman et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: A cancer and leukemia group B study
AB Kornblith et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
分享论文
